Integrin Receptor Antagonist [EPC]

218438 reported adverse events

Drugs of this class: NATALIZUMAB VEDOLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Integrin Receptor Antagonist [EPC] class:

# Side effect Count
0 FATIGUE 21648
1 MULTIPLE SCLEROSIS RELAPSE 15780
2 OFF LABEL USE 13782
3 DRUG INEFFECTIVE 11547
4 HEADACHE 11465
5 GAIT DISTURBANCE 9407
6 MULTIPLE SCLEROSIS 8936
7 ASTHENIA 8792
8 MALAISE 8692
9 FALL 8417
See all common reactions for Integrin Receptor Antagonist [EPC]

Drugs of the Integrin Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 THERAPEUTIC REACTION TIME DECREASED 1497 0.9100
1 VAGINAL FLATULENCE 71 0.6636
2 DRUG DELIVERY DEVICE IMPLANTATION 121 0.5475
3 JC VIRUS TEST POSITIVE 382 0.4515
4 LOSS OF THERAPEUTIC RESPONSE 450 0.4395
5 INFUSION SITE HAEMATOMA 142 0.4277
6 NEUTRALISING ANTIBODIES POSITIVE 118 0.3746
7 POOR VENOUS ACCESS 2591 0.3612
8 AGRAPHIA 189 0.3462
9 GENERAL SYMPTOM 2211 0.3378
See all enriched reactions for Integrin Receptor Antagonist [EPC]